- Home
- SXTP vs GRI Comparison
SXTP vs GRI Comparison
Compare SXTP & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SXTP
- GRI
- Stock Information
- Founded
- SXTP 2010
- GRI 2018
- Country
- SXTP United States
- GRI United States
- Employees
- SXTP N/A
- GRI N/A
- Industry
- SXTP Biotechnology: Pharmaceutical Preparations
- GRI Biotechnology: Pharmaceutical Preparations
- Sector
- SXTP Health Care
- GRI Health Care
- Exchange
- SXTP Nasdaq
- GRI Nasdaq
- Market Cap
- SXTP 3.7M
- GRI 3.2M
- IPO Year
- SXTP 2023
- GRI N/A
- Fundamental
- Price
- SXTP $2.34
- GRI $1.45
- Analyst Decision
- SXTP Buy
- GRI Strong Buy
- Analyst Count
- SXTP 2
- GRI 2
- Target Price
- SXTP $7.00
- GRI $22.00
- AVG Volume (30 Days)
- SXTP 118.8K
- GRI 108.0K
- Earning Date
- SXTP 08-13-2025
- GRI 08-13-2025
- Dividend Yield
- SXTP N/A
- GRI N/A
- EPS Growth
- SXTP N/A
- GRI N/A
- EPS
- SXTP N/A
- GRI N/A
- Revenue
- SXTP $802,323.00
- GRI N/A
- Revenue This Year
- SXTP $95.50
- GRI N/A
- Revenue Next Year
- SXTP $80.78
- GRI N/A
- P/E Ratio
- SXTP N/A
- GRI N/A
- Revenue Growth
- SXTP 118.37
- GRI N/A
- 52 Week Low
- SXTP $1.41
- GRI $1.10
- 52 Week High
- SXTP $35.99
- GRI $43.69
- Technical
- Relative Strength Index (RSI)
- SXTP 49.40
- GRI 50.67
- Support Level
- SXTP $2.31
- GRI $1.20
- Resistance Level
- SXTP $2.49
- GRI $1.47
- Average True Range (ATR)
- SXTP 0.18
- GRI 0.10
- MACD
- SXTP 0.01
- GRI 0.03
- Stochastic Oscillator
- SXTP 75.24
- GRI 85.50
About SXTP 60 Degrees Pharmaceuticals Inc.
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases.
About GRI GRI Bio Inc.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.